Literature DB >> 18389386

Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer.

T Myrhøj1, M-B Andersen, I Bernstein.   

Abstract

AIM: The aim of this study was to evaluate if Urine Cytology (UC) is an appropriate screening procedure for detecting urinary tract neoplasia at an early stage in persons at risk in Hereditary Non-Polyposis Colorectal Cancer families.
METHOD: In the National Danish HNPCC-register persons at risk were identified in three categories of HNPCC-families (1) families harbouring a disease causing mutation in a Mismatch repair gene (MMR), (2) families fulfilling the Amsterdam I or II criteria and (3) families suspected of HNPCC. In total 3,411 persons were identified and traced in Patobank-the National Danish Pathology database. All UC and UTC (Urinary Tract Tumours) were listed and evaluated.
RESULTS: 977 persons had a total of 1,868 screening procedures performed. Two of these procedures (0.1%) lead to diagnosis of an asymptomatic urothelial tumour. In ten times as many procedures (22 persons) UC lead to a false positive screening diagnosis. During the study period fourteen persons (1.4%) developed a UTC and five of these were interval tumours. The sensitivity of UC in diagnosing asymptomatic UTC in HNPCC patients was 29%. Twelve of the tumours were found in persons from families with a proven MMR-mutation and eleven out of these were MSH2 mutations (92%, 95% cl 62-100%). DISCUSSION: UC is not a proper method of screening for UTC in HNPCC. However, the study can not reveal if screening for UTC in special families ought to be recommended. Consequently, further studies needs to be performed in order to evaluate an appropriate screening programme.

Entities:  

Mesh:

Year:  2008        PMID: 18389386     DOI: 10.1007/s10689-008-9193-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  4 in total

1.  The accuracy of urinary cytology in daily practice.

Authors:  S Bastacky; S Ibrahim; S P Wilczynski; W M Murphy
Journal:  Cancer       Date:  1999-06-25       Impact factor: 6.860

2.  MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.

Authors:  H F Vasen; A Stormorken; F H Menko; F M Nagengast; J H Kleibeuker; G Griffioen; B G Taal; P Moller; J T Wijnen
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

3.  Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options.

Authors:  R H Sijmons; L A Kiemeney; J A Witjes; H F Vasen
Journal:  J Urol       Date:  1998-08       Impact factor: 7.450

Review 4.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).

Authors:  H F A Vasen; G Möslein; A Alonso; I Bernstein; L Bertario; I Blanco; J Burn; G Capella; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; J-P Mecklin; P Møller; F Nagengast; Y Parc; L Renkonen-Sinisalo; J R Sampson; A Stormorken; J Wijnen
Journal:  J Med Genet       Date:  2007-02-27       Impact factor: 6.318

  4 in total
  19 in total

1.  Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome.

Authors:  Jonathan W Wischhusen; Chinedu Ukaegbu; Tara G Dhingra; Hajime Uno; Fay Kastrinos; Sapna Syngal; Matthew B Yurgelun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10-15       Impact factor: 4.254

Review 2.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

3.  Uroepithelial and kidney carcinoma in Lynch syndrome.

Authors:  Markku Aarnio; Matti Säily; Matti Juhola; Annette Gylling; Päivi Peltomäki; Heikki J Järvinen; Jukka-Pekka Mecklin
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

4.  Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report.

Authors:  Cristian D Valenzuela; Harvey G Moore; William C Huang; Elsa W Reich; Herman Yee; Harry Ostrer; H Leon Pachter
Journal:  World J Surg Oncol       Date:  2009-12-08       Impact factor: 2.754

5.  Risks of Lynch syndrome cancers for MSH6 mutation carriers.

Authors:  Laura Baglietto; Noralane M Lindor; James G Dowty; Darren M White; Anja Wagner; Encarna B Gomez Garcia; Annette H J T Vriends; Nicola R Cartwright; Rebecca A Barnetson; Susan M Farrington; Albert Tenesa; Heather Hampel; Daniel Buchanan; Sven Arnold; Joanne Young; Michael D Walsh; Jeremy Jass; Finlay Macrae; Yoland Antill; Ingrid M Winship; Graham G Giles; Jack Goldblatt; Susan Parry; Graeme Suthers; Barbara Leggett; Malinda Butz; Melyssa Aronson; Jenny N Poynter; John A Baron; Loic Le Marchand; Robert Haile; Steve Gallinger; John L Hopper; John Potter; Albert de la Chapelle; Hans F Vasen; Malcolm G Dunlop; Stephen N Thibodeau; Mark A Jenkins
Journal:  J Natl Cancer Inst       Date:  2009-12-22       Impact factor: 13.506

6.  Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.

Authors:  Aung Ko Win; Noralane M Lindor; Joanne P Young; Finlay A Macrae; Graeme P Young; Elizabeth Williamson; Susan Parry; Jack Goldblatt; Lara Lipton; Ingrid Winship; Barbara Leggett; Katherine M Tucker; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Julie Arnold; A Joan Levine; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; John L Hopper; Mark A Jenkins
Journal:  J Natl Cancer Inst       Date:  2012-08-28       Impact factor: 13.506

Review 7.  Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review.

Authors:  Scott M Weissman; Cecelia Bellcross; Christina Chimera Bittner; Mary E Freivogel; Joy Larsen Haidle; Pardeep Kaurah; Anna Leininger; Selvi Palaniappan; Kelle Steenblock; Thuy M Vu; Molly S Daniels
Journal:  J Genet Couns       Date:  2010-10-08       Impact factor: 2.537

Review 8.  Surveillance for urinary tract cancer in Lynch syndrome.

Authors:  Inge Thomsen Bernstein; Torben Myrhøj
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 9.  Cancer risk in Lynch Syndrome.

Authors:  Emma Barrow; James Hill; D Gareth Evans
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 10.  EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.

Authors:  Glenn E Palomaki; Monica R McClain; Stephanie Melillo; Heather L Hampel; Stephen N Thibodeau
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.